Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas
نویسندگان
چکیده
منابع مشابه
Bromocriptine for visual field defects in prolactinomas.
The introduction of bromocriptine (2-brocergocryptine mesylate), a semi-synthetic ergot alkaloid, has revolutionised the treatment of the amenorrhoeagalactorrhoea syndrome due to excessive prolactin secretion (Thorner et. al., 1975). In a significant number of cases, this hyperprolactinaemia is caused by a radiologically obvious pituitary tumour (L'Hermite et. al., 1977; Bergh et al., 1978 a) w...
متن کاملmicroRNA expression profile and differentially-expressed genes in prolactinomas following bromocriptine treatment.
Little is known about the function of microRNAs in prolactinomas treated with bromocriptine. The aim of the study was to explore the microRNAs associated with bromocriptine-treated prolactinomas. Six prolactinoma samples were selected according to whether they received bromocriptine treatment or not before microsurgery, and microRNA expression pro...
متن کاملBromocriptine, dopamine and glaucoma.
The pharmacological control of intraocular pressure (IOP) is as complex as any other physiological system. The influence of the parasympathetic side of the autonomic nervous system, acting through muscarinic cholinergic receptors, has long been known, and cholinergic agonists such as pilocarpine are widely used in treatment of glaucoma. The sympathetic nervous system influences IOP in a remarka...
متن کاملBromocriptine and insulin secretion.
The dopaminergic drug bromocriptine inhibited the release of insulin from isolated mouse pancreatic islets. The effect was counteracted by haloperidol or pimozide. It is suggested that insulin release may be inhibited through activation of D-2 dopaminergic receptors in the pancreatic beta-cells.
متن کاملBromocriptine reduces cigarette smoking.
AIMS Animal studies have shown that nicotine releases dopamine, a neurotransmitter implicated in drug reinforcement. We hypothesized that bromocriptine would decrease smoking behavior in humans. DESIGN The study was conducted double blind and subjects' order of dose exposure was randomized. PARTICIPANTS The smoking behavior of 20 heavy smokers was recorded for 5 hours after ingesting placeb...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Cancer
سال: 1995
ISSN: 0007-0920,1532-1827
DOI: 10.1038/bjc.1995.520